HCW Biologics Inc. (HCWB): Nasdaq/NYSE listing notice — Nasdaq grants HCW Biologics extension to regain compliance by Dec 31, 2025

HCW Biologics Inc.

Nasdaq Hearings Panel granted extension to demonstrate compliance with Equity Rule by Dec 31, 2025, and all listing rules by Feb 16, 2026.
Company was non-compliant with Listing Rule 5550(b)(1) (minimum stockholders' equity) as of June 30, 2025.
Hearing held September 25, 2025; Panel considered Company's compliance plan.
Company must timely file Form 10-Q for Q3 and notify Nasdaq of significant events during exception period.
Panel may review its decision within 45 calendar days after written decision.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

HCW Biologics Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: extension granted
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

October 13, 2025, the Panel granted the Company an extension in which to regain compliance with all continued listing rules of the Exchange. The Panel’s determination follows the Company’s hearing on September 25, 2025, at which the Company presented, and the Panel considered, the Company’s plan to regain compliance with the Equity Rule. The Panel granted the Company’s request for continued listing on the Exchange, subject to, among other things, the Company demonstrating compliance with the Equity Rule by December 31, 2025, and with all other Exchange continued listing rules by February 16, 2

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

HCW Biologics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-240890

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.